Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine +

APOTEX HEALTH CORP. ANNOUNCES CLOSING OF UPSIZED INITIAL PUBLIC OFFERING AND EXERCISE OF OVER-ALLOTMENT OPTION IN FULL

Canadian pharma giant debuts on TSX with $1.5B capital raise, trading at a premium to IPO price

By The Northwire Desk — AI Analysis Jun 16, 2026 · 08:58 APTX · 28.6 APOTEX HEALTH CORP
Executive Summary
  • Apotex Health Corp. closed its upsized initial public offering (IPO) on the Toronto Stock Exchange (TSX) under the ticker APTX.
  • The offering consisted of 62,291,670 common shares priced at $24.00 per share, generating total gross proceeds of approximately $1.495 billion.
  • Proceeds are split between a primary treasury offering of ~35.4 million shares yielding ~$850 million to Apotex, and a secondary offering of ~26.9 million shares by SK Capital Partners and other existing shareholders yielding ~$645 million.
  • The underwriters' over-allotment option was exercised in full, adding 8,125,000 shares to the secondary offering, with proceeds going entirely to selling shareholders.
  • SK Capital Partners reduced its ownership stake from ~75.3% to ~52.4% post-offering, while Sherfam (API Investment LP) was diluted from ~16.8% to ~14.2%.
  • The transaction was co-led by major Canadian banks (RBC, TD, Scotiabank) and completed pursuant to a supplemented PREP prospectus dated June 10, 2026.
Material Impact
  • The closing confirms the successful completion of a major capital raise, but the event was fully anticipated and priced weeks in advance.
  • The stock has already traded at a significant premium to the IPO price, opening at $27.00 on June 10 and reaching $28.99 by June 12, indicating the market has already priced in the offering.
  • The full exercise of the over-allotment option signals strong institutional demand, which typically provides a liquidity floor and supports the initial valuation.
  • However, the secondary offering represents substantial insider selling (~$645 million), with SK Capital offloading a meaningful portion of its stake. This reduces insider alignment and introduces near-term selling pressure that could cap upside.
  • The $850 million in primary proceeds will strengthen the balance sheet, but without disclosed use-of-proceeds or financials, the immediate operational impact is neutral.
APTX · Price
Company Overview
  • Apotex Health Corp. is the largest Canadian-based pharmaceutical company, headquartered in Toronto with regional offices in the United States, Mexico, and India.
  • The company operates a broad portfolio spanning generic, biosimilar, and innovative branded pharmaceuticals, alongside consumer health products.
  • Strategic positioning emphasizes delivering affordable, high-quality medicines and serving as a preferred health partner in the Americas for pharmaceutical licensing and product acquisitions.
  • The company completed one of the largest life sciences IPOs in TSX history by total proceeds.
Read the original news release →

More from APOTEX HEALTH CORP

Jul 01, 2026 · 09:00

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

M&A / Property Jul 01, 2026 · 01:47

Apotex Health receives Health Canada OK for Sevmia

Regulatory Jun 30, 2026 · 16:19

Apotex Capitalizes on GLP-1 Boom with First Canadian Generic Weight-Loss Approval Post-IPO

Regulatory Jun 11, 2026 · 11:18

Canadian pharma giant completes $1.3B IPO, debuts on TSX with a 12.5% pop.

Regulatory Jun 10, 2026 · 09:01

Record $1.3B life sciences IPO launches on TSX, valuing Canada's largest pharma at ~$5.6B.

Regulatory Jun 09, 2026 · 20:38

APOTEX HEALTH CORP. FILES FINAL PROSPECTUS AND ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERING

Financings